
Elypta’s urine test identifies 90% of recurrent kidney cancer cases
Swedish cancer diagnostic company Elypta’s urine test has been able to accurately identify 90% of patients with recurrent kidney cancer. The business announced the intermediary results from its prospective multi-centre trial designed to determine if urine- …